This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nagueh, S. F. Articles by Spencer, W. H. Search for Related Content PubMed PubMed Citation Articles by Nagueh, S. F. Articles by Spencer, W. H., III

CLINICAL STUDIES

Role of myocardial contrast echocardiography during nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy

^a Department of Medicine, Section of Cardiology, Baylor College of Medicine, Houston, Texas, USA

Manuscript received December 11, 1997; revised manuscript received March 17, 1998, accepted April 9, 1998.

Address for correspondence: Dr. Sherif F. Nagueh, Section of Cardiology, Baylor College of Medicine, 6550 Fannin, SM1246, Houston, Texas 77030
sherifn{at}bcm.tmc.edu

Objectives. This study was undertaken to evaluate the ability of myocardial contrast echocardiography (MCE) to guide the targeted delivery of ethanol during nonsurgical septal reduction therapy (NSRT) and to assess the relation between the MCE risk area and infarct size determined by enzymatic and radionuclide methods.

Background. NSRT with intracoronary ethanol is a new promising treatment for patients with hypertrophic obstructive cardiomyopathy (HOCM). Proper localization and quantification of the septal infarct before ethanol injection are highly desirable. MCE can provide accurate delineation of the vascular territory of the coronary arteries.

Methods. Twenty-nine patients with HOCM and maximal medical therapy underwent NSRT. The left ventricular outflow tract (LVOT) gradient by Doppler echocardiography at baseline was 53 ± 16 mm Hg (mean ± SD). Before NSRT, MCE was performed in all patients with intracoronary sonicated albumin (Albunex). Diluted sonicated albumin (Albunex) was selectively injected into the septal perforator arteries during simultaneous transthoracic imaging. Immediately after MCE, ethanol was injected into the same vessel. Plasma total creatine kinase (CK), total CK-MB fraction and CK-MB fraction subforms were measured at baseline and serially for 36 h.

Results. LVOT gradient decreased to 12 ± 6 mm Hg (p < 0.001) after NSRT. Accurate mapping of the vascular beds of the septal perforators was successfully attained in all patients by MCE. Furthermore, the MCE risk area correlated well with peak CK (r = 0.79, p < 0.001). Six weeks after NSRT, 23 patients underwent myocardial perfusion studies performed with single-photon emission computed tomography (SPECT). Mean SPECT septal perfusion defect size involved 9.5 ± 6% of the left ventricle and correlated well with MCE area (r = 0.7), with no statistically significant difference between the risk area estimated by MCE and that by SPECT.

Conclusions. Estimation of the size of the septal vascular territory with MCE is accurate, safe and feasible in essentially all patients during NSRT. MCE can delineate the perfusion bed of the septal perforators and can predict the infarct size that follows ethanol injection.

Abbreviations and Acronyms   CK = creatine kinase   HOCM = hypertrophic obstructive cardiomyopathy   LAD = left anterior descending coronary artery   LVOT = left ventricular outflow tract   MCE = myocardial contrast echocardiography (echocardiographic)   NSRT = nonsurgical septal reduction therapy   SPECT = single-photon emission computed tomography (tomographic)

This article has been cited by other articles:

				M. Alam, H. Dokainish, and N. M. Lakkis Hypertrophic obstructive cardiomyopathy-alcohol septal ablation vs. myectomy: a meta-analysis Eur. Heart J., May 1, 2009; 30(9): 1080 - 1087. [Abstract] [Full Text] [PDF]

				S. K. Dhar, V. Varadharajan, A. Al-Mohammad, J. Sandoval, and E. D Grech Symptomatic hypertrophic obstructive cardiomyopathy: semi-supine bicycle ergometry as a useful provocative manoeuvre to elicit latent gradient BMJ Case Reports, March 30, 2009; 2009(mar30_1): bcr1020081044 - bcr1020081044. [Abstract] [Full Text]

				L. C. Afonso, J. Bernal, J. J. Bax, and T. P. Abraham Echocardiography in hypertrophic cardiomyopathy: the role of conventional and emerging technologies. J. Am. Coll. Cardiol. Img., November 1, 2008; 1(6): 787 - 800. [Abstract] [Full Text] [PDF]

				S. Kaul Myocardial Contrast Echocardiography: A 25-Year Retrospective Circulation, July 15, 2008; 118(3): 291 - 308. [Full Text] [PDF]

				U. S. Valeti, R. A. Nishimura, D. R. Holmes, P. A. Araoz, J. F. Glockner, J. F. Breen, S. R. Ommen, B. J. Gersh, A. J. Tajik, C. S. Rihal, et al. Comparison of Surgical Septal Myectomy and Alcohol Septal Ablation With Cardiac Magnetic Resonance Imaging in Patients With Hypertrophic Obstructive Cardiomyopathy J. Am. Coll. Cardiol., January 23, 2007; 49(3): 350 - 357. [Abstract] [Full Text] [PDF]

				S. F. Nagueh and J. J. Mahmarian Noninvasive Cardiac Imaging in Patients With Hypertrophic Cardiomyopathy J. Am. Coll. Cardiol., December 19, 2006; 48(12): 2410 - 2422. [Abstract] [Full Text] [PDF]

				W. G. van Dockum, J. P.A. Kuijer, M. J.W. Gotte, F. J. ten Cate, J. M. ten Berg, A. M. Beek, J. W.R. Twisk, J. T. Marcus, C. A. Visser, and A. C. van Rossum Septal ablation in hypertrophic obstructive cardiomyopathy improves systolic myocardial function in the lateral (free) wall: a follow-up study using CMR tissue tagging and 3D strain analysis Eur. Heart J., December 1, 2006; 27(23): 2833 - 2839. [Abstract] [Full Text] [PDF]

				W. G. van Dockum, F. J. ten Cate, J. M. ten Berg, A. M. Beek, J. W. R. Twisk, J. Vos, M. B. M. Hofman, C. A. Visser, and A. C. van Rossum Myocardial infarction after percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: evaluation by contrast-enhanced magnetic resonance imaging J. Am. Coll. Cardiol., January 7, 2004; 43(1): 27 - 34. [Abstract] [Full Text] [PDF]

				B. J. Maron, W. J. McKenna, G. K. Danielson, L. J. Kappenberger, H. J. Kuhn, C. E. Seidman, P. M. Shah, W. H. Spencer III, P. Spirito, F. J. Ten Cate, et al. American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines J. Am. Coll. Cardiol., November 5, 2003; 42(9): 1687 - 1713. [Full Text] [PDF]

				Writing Committee Members, B. J. Maron, W. J. McKenna, G. K. Danielson, L. J. Kappenberger, H. J. Kuhn, C. E. Seidman, P. M. Shah, W. H. Spencer III, P. Spirito, et al. American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy: A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines Eur. Heart J., November 1, 2003; 24(21): 1965 - 1991. [Full Text] [PDF]

				M. V. Sherrid, F. A. Chaudhry, and D. G. Swistel Obstructive hypertrophic cardiomyopathy: echocardiography, pathophysiology, and the continuing evolution of surgery for obstruction Ann. Thorac. Surg., February 1, 2003; 75(2): 620 - 632. [Abstract] [Full Text] [PDF]

				U. Sigwart Non-surgical myocardial reduction for patients with hypertrophic obstructive cardiomyopathy Eur. Heart J. Suppl., October 1, 2001; 3(suppl_L): L38 - L42. [Abstract] [PDF]

				N. M. Lakkis, S. F. Nagueh, J. K. Dunn, D. Killip, and W. H. Spencer III Nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy: one-year follow-up J. Am. Coll. Cardiol., September 1, 2000; 36(3): 852 - 855. [Abstract] [Full Text] [PDF]

				H. Seggewiss Percutaneous transluminal septal myocardial ablation: A new treatment for hypertrophic obstructive cardiomyopathy Eur. Heart J., May 1, 2000; 21(9): 704 - 707. [PDF]

				W Ruzyllo, L Chojnowska, M Demkow, A Witkowski, B Kusmierczyk-Droszcz, W Piotrowski, L Rausinska, M Karcz, L Malecka, and W Rydlewska-Sadowska Left ventricular outflow tract gradient decrease with non-surgical myocardial reduction improves exercise capacity in patients with hypertrophic obstructive cardiomyopathy Eur. Heart J., May 1, 2000; 21(9): 770 - 777. [Abstract] [PDF]

				P M Elliott, S J Brecker, and W J McKenna Left ventricular opacification during selective intracoronary injection of echocardiographic contrast in patients with hypertrophic cardiomyopathy Heart, April 1, 2000; 83(4): 7e - 7. [Abstract] [Full Text]

				H. Kuhn, F.H. Gietzen, M. Schafers, M. Freick, B. Gockel, C. Strunk-Muller, E. Jachmann, and O. Schober Changes in the left ventricular outflow tract after transcoronary ablation of septal hypertrophy (TASH) for hypertrophic obstructive cardiomyopathy as assessed by transoesophageal echocardiography and by measuring myocardial glucose utilization and perfusion Eur. Heart J., December 2, 1999; 20(24): 1808 - 1817. [Abstract] [PDF]